content: <PAGE>
  
  ================================================================================
  
                        SECURITIES AND EXCHANGE COMMISSION
                              Washington, D.C.  20549
  
  
  
  
  
                                     FORM 8-K
  
  
  
  
                                  CURRENT REPORT
                        Pursuant to Section 13 or 15(d) of
                        The Securities Exchange Act of 1934
  
  
                           Date of Report: July 6, 1999
                         (Date of earliest event reported)
  
  
                                 drkoop.com, Inc.
              (exact name of registrant as specified in its charter)
  
  
            Delaware                Commission File:               95-4697615
  (State or other jurisdiction         000-26275                (I.R.S. Employer
       of incorporation or                                     Identification No.)
          organization)
  
  
  
                             8920 Business Park Drive
                                Austin, Texas 78759
           (Address of Principal executive offices, including zip code)
  
  
  
                                  (512) 726-5110
               (Registrant's telephone number, including area code)
  
  
  ================================================================================
  <PAGE>
  
  ITEM 5.  OTHER EVENTS.
  
       On July 6, 1999, our company, drkoop.com, Inc., a Delaware corporation (the
  "Company"), and American Online, Inc. ("AOL") jointly disseminated a press
  release announcing a four-year, strategic alliance between the two companies.
  That press release is attached to this Report as Exhibit 5.1 and is incorporated
  herein by this reference.  The incorporated press release shall not be deemed to
  include any material in any of the hyperlinks to Internet sites included
  therein.
  
       As indicated in the press release, the compensation payable to AOL includes
  cash and warrants to purchase drkoop.com common stock.  The warrants consist of
  the following:
  
       .  Warrants to purchase 1,570,932 shares of our common stock for a purchase
          price of $15.94 per share (the closing price on June 30, 1999). These
          warrants are fully vested and may be exercised at any time on or after
          June 30, 2000 and on or prior to June 30, 2008, subject to limited
          exceptions relating to a change in control of drkoop.com or the early
          termination of the Interactive Services Agreement between AOL and
          drkoop.com.
  
       .  Warrants to purchase up to 1,570,932 shares of our common stock for a
          purchase price of $20.00 per share. These warrants are not exercisable,
          and will not become exercisable unless the AOL relationship delivers to
          drkoop.com during the four years of the Interactive Services Agreement
          traffic (measured in page views) at or above agreed upon levels.
          Accordingly, one-fourth of these warrants (i.e., 392,733 warrants) could
          become vested in each of the next four years if those performance
          hurdles are met. Any warrants that become vested will be exercisable at
          any time on or prior to June 30, 2008
  
       .  Warrants to purchase up to 2,749,131 shares of our common stock. These
          warrants are not exercisable, and will not become exercisable unless the
          AOL relationship delivers specified usage of a new personal medical
          records software tool to be developed by drkoop.com and jointly deployed
          by drkoop.com and AOL. The warrant specifies four performance hurdles,
          measured by usage of the new tool, which if accomplished will result in
          392,733, 392,733, 785,466 and 1,178,199 warrants becoming vested and
          exercisable. The exercise price of these warrants will be established at
          the time they become vested and will be calculated as 80%, 75%, 70% and
          65% of fair market value at such time. Any warrants that become vested
          will be exercisable at any time on or prior to June 30, 2008.
  
       All of the warrants include customary ancillary provisions, including anti-
  dilution adjustments for stock splits, stock dividends and similar structural
  changes.  None of the warrants may be transferred prior to December 8, 1999 or
  if the related warrants have not vested.  A change in control transaction
  involving drkoop.com could result in an acceleration of the vesting of these
  warrants.
  
       The parties also entered into a registration rights agreement which could
  require that drkoop.com register any shares of common stock issued to AOL upon
  exercise of any warrant for resale under the Securities Act of 1933, although
  these rights are subordinated to the rights
  
                                         2
  <PAGE>
  
  previously granted in the Amended and Restated Registration Rights Agreement
  dated January 29, 1999.
  
       In connection with this strategic alliance, AOL will also pay to drkoop.com
  approximately $8 million related to specified technology to be provided to AOL
  by drkoop.com.
  
       This Report includes forward-looking statements that are based on current
  expectations and involve risks and uncertainties. drkoop.com cannot guarantee
  that actual future events will not vary materially from those described in this
  Report. Specifically, the nature and deployment of new products and services is
  subject to revision due to technical and other factors, and such products and
  services may not be accepted by consumers. In addition, our traffic growth is
  subject to our ability to continue to attract and retain our audience of users
  by providing healthcare content, tools and other features which meet the
  changing demands of those users. For a further discussion of the business risks
  faced by drkoop.com, please see the section captioned "Risk Factors" in our
  final prospectus filed June 8, 1999 with the Securities and Exchange Commission.
  drkoop.com undertakes no obligation to update any of the forward-looking
  statements in this Report.
  
  
  
                                   *  *  *  *  *
  
                                         3
  <PAGE>
  
  ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA INFORMATION AND EXHIBITS.
  
  (a)  Financial Statements of Business Acquired.
  
       Not applicable.
  
  (b)  Pro Forma Financial Information.
  
       Not applicable.
  
  (c)  Exhibits
  
       5.1  Joint Press Release dated July 6, 1999
  
                                         4
  <PAGE>
  
                                     SIGNATURES
  
  
  
       Pursuant to the requirements of the Securities Exchange Act of 1934, the
  Registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized,
  
  
                                          drkoop.com, Inc.
  
  
  
  Date:  July 6, 1999            By  /S/  Susan M. Georgen-Saad
                                     --------------------------
                                    Name:  Susan M. Georgen-Saad
                                    Title: Chief Financial Officer
  
                                         5
  <PAGE>
  
                                   EXHIBIT INDEX
  
                                                              Sequentially
  Exhibit                                                       Numbered
    No.            Description                                    Page
  -------          -----------                                ------------
    5.1            Joint Press Release dated July
                   6, 1999
  
  
  
  
                                   *  *  *  *  *
  
                                         6
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "FORM 8-K", "secsgml_size_bytes": 7473}]
metadata_filer: {"company-data": {"conformed-name": "DRKOOP COM", "cik": "0001073794", "assigned-sic": "8090", "irs-number": "954697615", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26275", "film-number": "99659806"}, "business-address": {"street1": "8920 BUSINESS PARK DR", "street2": "C/O EMPOWER HEALTH CORP", "city": "AUSTIN", "state": "TX", "zip": "78759", "phone": "5127265110"}, "mail-address": {"street1": "EMPOWER HEALTH CORP", "street2": "8920 BUSINESS PARK DRIVE", "city": "AUSTIN", "state": "TX", "zip": "78759"}, "former-company": {"former-conformed-name": "EMPOWER HEALTH CORP", "date-changed": "19990224"}}
text: ================================================================================
  
                        SECURITIES AND EXCHANGE COMMISSION
                              Washington, D.C.  20549
  
                                     FORM 8-K
  
                                  CURRENT REPORT
                        Pursuant to Section 13 or 15(d) of
                        The Securities Exchange Act of 1934
  
                           Date of Report: July 6, 1999
                         (Date of earliest event reported)
  
                                 drkoop.com, Inc.
              (exact name of registrant as specified in its charter)
  
            Delaware                Commission File:               95-4697615
  (State or other jurisdiction         000-26275                (I.R.S. Employer
       of incorporation or                                     Identification No.)
          organization)
  
                             8920 Business Park Drive
                                Austin, Texas 78759
           (Address of Principal executive offices, including zip code)
  
                                  (512) 726-5110
               (Registrant's telephone number, including area code)
  
  ================================================================================
  ITEM 5.  OTHER EVENTS.
  
       On July 6, 1999, our company, drkoop.com, Inc., a Delaware corporation (the
  "Company"), and American Online, Inc. ("AOL") jointly disseminated a press
  release announcing a four-year, strategic alliance between the two companies.
  That press release is attached to this Report as Exhibit 5.1 and is incorporated
  herein by this reference.  The incorporated press release shall not be deemed to
  include any material in any of the hyperlinks to Internet sites included
  therein.
  
       As indicated in the press release, the compensation payable to AOL includes
  cash and warrants to purchase drkoop.com common stock.  The warrants consist of
  the following:
  
       .  Warrants to purchase 1,570,932 shares of our common stock for a purchase
          price of $15.94 per share (the closing price on June 30, 1999). These
          warrants are fully vested and may be exercised at any time on or after
          June 30, 2000 and on or prior to June 30, 2008, subject to limited
          exceptions relating to a change in control of drkoop.com or the early
          termination of the Interactive Services Agreement between AOL and
          drkoop.com.
  
       .  Warrants to purchase up to 1,570,932 shares of our common stock for a
          purchase price of $20.00 per share. These warrants are not exercisable,
          and will not become exercisable unless the AOL relationship delivers to
          drkoop.com during the four years of the Interactive Services Agreement
          traffic (measured in page views) at or above agreed upon levels.
          Accordingly, one-fourth of these warrants (i.e., 392,733 warrants) could
          become vested in each of the next four years if those performance
          hurdles are met. Any warrants that become vested will be exercisable at
          any time on or prior to June 30, 2008
  
       .  Warrants to purchase up to 2,749,131 shares of our common stock. These
          warrants are not exercisable, and will not become exercisable unless the
          AOL relationship delivers specified usage of a new personal medical
          records software tool to be developed by drkoop.com and jointly deployed
          by drkoop.com and AOL. The warrant specifies four performance hurdles,
          measured by usage of the new tool, which if accomplished will result in
          392,733, 392,733, 785,466 and 1,178,199 warrants becoming vested and
          exercisable. The exercise price of these warrants will be established at
          the time they become vested and will be calculated as 80%, 75%, 70% and
          65% of fair market value at such time. Any warrants that become vested
          will be exercisable at any time on or prior to June 30, 2008.
  
       All of the warrants include customary ancillary provisions, including anti-
  dilution adjustments for stock splits, stock dividends and similar structural
  changes.  None of the warrants may be transferred prior to December 8, 1999 or
  if the related warrants have not vested.  A change in control transaction
  involving drkoop.com could result in an acceleration of the vesting of these
  warrants.
  
       The parties also entered into a registration rights agreement which could
  require that drkoop.com register any shares of common stock issued to AOL upon
  exercise of any warrant for resale under the Securities Act of 1933, although
  these rights are subordinated to the rights
  
                                         2
  previously granted in the Amended and Restated Registration Rights Agreement
  dated January 29, 1999.
  
       In connection with this strategic alliance, AOL will also pay to drkoop.com
  approximately $8 million related to specified technology to be provided to AOL
  by drkoop.com.
  
       This Report includes forward-looking statements that are based on current
  expectations and involve risks and uncertainties. drkoop.com cannot guarantee
  that actual future events will not vary materially from those described in this
  Report. Specifically, the nature and deployment of new products and services is
  subject to revision due to technical and other factors, and such products and
  services may not be accepted by consumers. In addition, our traffic growth is
  subject to our ability to continue to attract and retain our audience of users
  by providing healthcare content, tools and other features which meet the
  changing demands of those users. For a further discussion of the business risks
  faced by drkoop.com, please see the section captioned "Risk Factors" in our
  final prospectus filed June 8, 1999 with the Securities and Exchange Commission.
  drkoop.com undertakes no obligation to update any of the forward-looking
  statements in this Report.
  
                                   *  *  *  *  *
  
                                         3
  ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA INFORMATION AND EXHIBITS.
  
  (a)  Financial Statements of Business Acquired.
  
       Not applicable.
  
  (b)  Pro Forma Financial Information.
  
       Not applicable.
  
  (c)  Exhibits
  
       5.1  Joint Press Release dated July 6, 1999
  
                                         4
  SIGNATURES
  
       Pursuant to the requirements of the Securities Exchange Act of 1934, the
  Registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized,
  
                                          drkoop.com, Inc.
  
  Date:  July 6, 1999            By  /S/  Susan M. Georgen-Saad
                                     --------------------------
                                    Name:  Susan M. Georgen-Saad
                                    Title: Chief Financial Officer
  
                                         5
  EXHIBIT INDEX
  
                                                              Sequentially
  Exhibit                                                       Numbered
    No.            Description                                    Page
  -------          -----------                                ------------
    5.1            Joint Press Release dated July
                   6, 1999
  
                                   *  *  *  *  *
  
                                         6